

IN THE SPECIFICATION

Please **amend** paragraph [0009] as follows:

[0009] In another embodiment of the invention, the antimicrobial peptides are LLP1 analogs having modifications based on the following principles: (i) optimizing amphipathicity, (ii) substituting arginine (Arg) on the charged face and/or valine (Val) or tryptophan (Trp) on the hydrophobic face with another amino acid, and (iii) increasing peptide length (referred to collectively herein as LBU peptides, ~~e.g. LBU-2~~(e.g. LBU-1, SEQ ID NO:4; ~~LBU-3~~LBU-2, SEQ ID NO:5; ~~LBU-3.5~~LBU-3, SEQ ID NO:6; ~~LBU-4~~LBU-3.5, SEQ ID NO:7; ~~WLBU-1~~LBU-4, SEQ ID NO:8, ~~WLBU-2~~WLBU-1, SEQ ID NO:9, ~~WLBU-3~~WLBU-2, SEQ ID NO:10; and ~~WLBU-4~~; WLBU-3, WLBU-4; SEQ ID NO:11; and WLBU-4, SEQ ID NO:12; see Table 1). The LBU peptides deviate greatly from the parent LLPI, for example, LBU-2 and LBU-3 deviate from the parent LLP1 sequence by greater than 90%.

TABLE 1

SA-5:	RVIRV VQRAC RAIRH IVRRI RQGLR RIL	(SEQ ID NO: 1)
LSA-5:	RVIRV VQRAC RAIRH IVRRI RQGLR RILRV V	(SEQ ID NO: 2)
WLSA-5:	RWIRV VQRWC RAIRH IWRRI RQGLR RWLRV V	(SEQ ID NO: 3)
LBU-1	RVVRV VRRVV RR	(SEQ ID NO:4)
LBU-2:	RRVVR RVRRV VRRVV RVVRR VVRR	(SEQ ID NO: 5)
LBU-3 :	VRRVV RRVVR VVRRV VRRVR RVVRR VVRVV RRVVR	(SEQ ID NO: 6)
LBU-3.5	RRVVR RVRRV VRRVV RVVRR VVRRV RVVVR RVVRV VRRVV RR	(SEQ ID NO:7)
LBU-4	RVVRV VRRVV RVVRR VVRRV RVVVR RVVRR VRRVV RVVVR VVRRV VRR	(SEQ ID NO:8)
WLBU-1	RVVRV VRRWV RR	(SEQ ID NO:9)
WLBU-2	RRWVR RVRRV WRRVV RVVRR WVRR	(SEQ ID NO:10)
WLBU-3	VRRVW RVVVR VVRRW VRRVR RVWRR VVRVV RRWVR R	(SEQ ID NO:11)
WLBU-4	RVVRV VRRWV RVVRR VVRRV RVVVR RVVRR VRRVW RVVVR VVRRW RVVVR	(SEQ ID NO:12)

IN THE DRAWINGS

Please **replace** the informal drawings of record with the Formal Drawings enclosed herewith.

IN THE SEQUENCE LISTING

Please **replace** the sequence listing of record with the Substitute Sequence Listing enclosed herewith.